Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Capital Employed (2016 - 2026)

Neurocrine Biosciences filings provide 15 years of Return on Capital Employed readings, the most recent being 16.71% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 158.0% to 16.71% in Q4 2025 year-over-year; TTM through Dec 2025 was 16.71%, a 158.0% decrease, with the full-year FY2025 number at 18.04%, down 112.0% from a year prior.
  • Return on Capital Employed hit 16.71% in Q4 2025 for Neurocrine Biosciences, up from 16.0% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 19.36% in Q3 2024 to a low of 3.69% in Q2 2022.
  • Median Return on Capital Employed over the past 5 years was 11.22% (2021), compared with a mean of 11.7%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -2448bps in 2021 and later skyrocketed 1091bps in 2024.
  • Neurocrine Biosciences' Return on Capital Employed stood at 5.7% in 2021, then soared by 154bps to 14.49% in 2022, then dropped by -28bps to 10.48% in 2023, then surged by 75bps to 18.29% in 2024, then fell by -9bps to 16.71% in 2025.
  • The last three reported values for Return on Capital Employed were 16.71% (Q4 2025), 16.0% (Q3 2025), and 15.27% (Q2 2025) per Business Quant data.